In parallel, a critical reduction of IL-1β, IL-1RA, IL-6, and TNF-α concentration was evident 2 days after MSC infusion, mimicking the effectiveness of other immunomodulatory agents, such as baricitinib [17], in dampening COVID-19-associated inflammation. The gene discussed is IL1B; the disease is COVID-19.